As per Regulation 30 of SEBI (LODR)Regulation,2015 uploading our Audited Financial Results for the Quarter and Year Ended on 31-03-2025. Kindly take the same on records.

Revenue declinedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.9%Reaction day

₹58.00

prior close

₹60.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.2%-2.1% vs market

Pharmaceuticals peers, median of 150sector+1.0%-1.8% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.2

15m

-0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.9+1.2-2.1+1.0-1.8

Next day

-1.7+0.1-1.8-0.2-1.6

-6.6+0.9-7.5+0.6-7.3

-2.0+0.8-2.8+0.2-2.2

+1.7+1.4+0.3+0.1+1.6

+3.4+2.0+1.4+0.5+2.9

+8.3+2.3+6.0+1.5+6.8

15d

+3.6+5.2-1.5+1.4+2.2

-11.8+1.6-13.3-1.4-10.3

-7.2+7.7-14.9+3.7-11.0

-27.2+4.0-31.2-0.2-27.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Colinz Laboratories reported audited results for FY25 showing revenue from operations of Rs 652.77 lakhs, down about 7% from Rs 702.96 lakhs in FY24. Q4 revenue also fell to Rs 145.14 lakhs from Rs 162.94 lakhs a year earlier. Despite the revenue dip, profit after tax inched up modestly to Rs 49.66 lakhs (FY24: Rs 48.67 lakhs), with Q4 PAT rising to Rs 15.04 lakhs from Rs 13.60 lakhs. Full-year EPS stood at Rs 1.97 versus Rs 1.93. The statutory auditor (Vora & Associates) issued an unmodified (clean) opinion on the results. The board also approved the appointment of an additional director during the meeting.

Likely market impact

Flat-to-mildly positive earnings despite a revenue dip signal some margin discipline, but the top-line contraction and a sharp swing to negative operating cash flow (Rs -145.37 lakhs vs Rs +103.47 lakhs last year) are concerns for shareholders. Short-term share price reaction may be muted given the small scale of operations.